Appl. Serial No.: 09/881,050
Attorney Docket No.: BERLX-88
Reply Dated December 15, 2003

 $A_1 = A_1$ 

- Ar Re

ŖĊ.

13

 $P_{\alpha}$ 

١;

Reply to Office Action of August 14, 2003

This listing of claims will replace all prior versions, and listings, of claims in the application: Listing of Claims:

- 1. (Currently Amended) A pharmaceutical composition useful in treating multiple sclerosis in mammals, which a mammal, wherein said composition comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-beta2 polypeptide, a biologically-active fragment thereof, or a biologically-active derivative thereof.
- 2. (Currently Amended) The pharmaceutical composition of Claim 1, wherein the mammal in need thereof said mammal is human.
- 3. (Currently Amended) A method of administering to a mammal in need thereof a pharmaceutical composition useful in <u>treating</u> multiple sclerosis in <u>mammals</u>, <u>which a mammal</u>, <u>wherein said</u> composition comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-beta2 polypeptide, a biologically-active fragment thereof, or a biologically-active derivative thereof, <u>wherein said method of</u> administering comprises administering said composition to said mammal.
- 4. (Currently Amended) The method of Claim 3, wherein the mammal in need thereof is a human.
- 5. (New) A method of treating multiple sclerosis comprising administering to a mammal in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-beta2 polypeptide, a biologically-active fragment thereof, or a biologically-active derivative thereof.